Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$35.48 USD
+0.65 (1.87%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $35.46 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$35.48 USD
+0.65 (1.87%)
Updated Oct 14, 2024 03:59 PM ET
After-Market: $35.46 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Zacks News
Bears are Losing Control Over Harmony Biosciences Holdings, Inc. (HRMY), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Does Harmony Biosciences Holdings, Inc. (HRMY) Have the Potential to Rally 32.19% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 32.2% in Harmony Biosciences Holdings, Inc. (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
All You Need to Know About Harmony Biosciences Holdings, Inc. (HRMY) Rating Upgrade to Buy
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
HRMY or ACAD: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRMY vs. ACAD: Which Stock Is the Better Value Option?
HRMY or GMAB: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRMY vs. GMAB: Which Stock Is the Better Value Option?
Wall Street Analysts Predict a 44.38% Upside in Harmony Biosciences Holdings, Inc. (HRMY): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 44.4% in Harmony Biosciences Holdings, Inc. (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
HRMY vs. REGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
HRMY vs. REGN: Which Stock Is the Better Value Option?
How Much Upside is Left in Harmony Biosciences Holdings, Inc. (HRMY)? Wall Street Analysts Think 76.62%
by Zacks Equity Research
The mean of analysts' price targets for Harmony Biosciences Holdings, Inc. (HRMY) points to a 76.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HRMY vs. REGN: Which Stock Is the Better Value Option?
Harmony Biosciences Holdings, Inc. (HRMY) Lags Q3 Earnings Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of -5.97% and 11.39%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Expected to Decline
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harmony Biosciences Holdings, Inc. (HRMY) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of -9.68% and 3.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 9.09% and 0.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Harmony Biosciences Holdings, Inc. (HRMY) Soars 8.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 87.04% and 0.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Strength Seen in Harmony Biosciences Holdings, Inc. (HRMY): Can Its 5.1% Jump Turn into More Strength?
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Harmony Biosciences (HRMY) Stock Might be a Great Pick
by Zacks Equity Research
Harmony Biosciences (HRMY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Harmony Biosciences Holdings, Inc. (HRMY) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 850% and 3.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.